LON:ABZA - ABZENA/PAR VTG FPD 0.002 Stock Price, News & Analysis

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average Volume26,706 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Abzena plc provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. It provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. Read More…

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive ABZA News and Ratings via Email

Sign-up to receive the latest news and ratings for ABZA and its competitors with MarketBeat's FREE daily newsletter.

ABZENA/PAR VTG FPD 0.002 (LON:ABZA) Frequently Asked Questions

What is ABZENA/PAR VTG FPD 0.002's stock symbol?

ABZENA/PAR VTG FPD 0.002 trades on the London Stock Exchange (LON) under the ticker symbol "ABZA."

Has ABZENA/PAR VTG FPD 0.002 been receiving favorable news coverage?

News coverage about ABZA stock has trended negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ABZENA/PAR VTG FPD 0.002 earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for ABZENA/PAR VTG FPD 0.002.

Who are some of ABZENA/PAR VTG FPD 0.002's key competitors?

What other stocks do shareholders of ABZENA/PAR VTG FPD 0.002 own?

Who are ABZENA/PAR VTG FPD 0.002's key executives?

ABZENA/PAR VTG FPD 0.002's management team includes the folowing people:
  • Dr. William John Edward Burt, CEO & Exec. Director (Age 50)
  • Prof. Sunil Shaunak, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Antony Godwin Ph.D., Co-Founder
  • Prof. Steve Brocchini Ph.D., Co-Founder
  • Dr. Jim Mills, Sr. VP of Technical Operations

How do I buy shares of ABZENA/PAR VTG FPD 0.002?

Shares of ABZA and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ABZENA/PAR VTG FPD 0.002's official website?

The official website for ABZENA/PAR VTG FPD 0.002 is http://www.abzena.com/.

How can I contact ABZENA/PAR VTG FPD 0.002?

ABZENA/PAR VTG FPD 0.002's mailing address is Babraham Hall, Babraham Research, CAMBRIDGE, CB22 3AT, United Kingdom. The company can be reached via phone at +44-1223-903498.

MarketBeat Community Rating for ABZENA/PAR VTG FPD 0.002 (LON ABZA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about ABZENA/PAR VTG FPD 0.002 and other stocks. Vote "Outperform" if you believe ABZA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABZA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel